.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 3,928,601

« Back to Dashboard

Details for Patent: 3,928,601

Title: Phenoxy-hydroxypropylamines, method and pharmaceutical preparations for treating cardiovascular diseases
Abstract:Para-substituted phenoxy-hydroxypropylamines having the general formula ##SPC1## And pharmaceutically acceptable, non-toxic acid addition salts thereof, wherein R' is an isopropyl or tertiarybutyl radical; Z is a member selected from the group consisting of --OR", --SR", and --NHCOOR", R" being a straight or branched lower alkyl radical having 1 to 3 carbon atoms; and n is 1, 2, or 3, are disclosed as are methods for their preparation. Pharmaceutical preparations are prepared whose active ingredients include at least one of the newly discovered phenoxy-hydroxypropylamine compounds. Therapeutically effective doses of these preparations selectively block the .beta.-receptors of the heart making them useful in treating heart diseases in animals including humans.
Inventor(s): Brandstrom; Arne Elof (Goteborg, SW), Carlsson; Per Arvid Emil (Goteborg, SW), Carlsson; Stig Ake Ingemar (Molnlycke, SW), Corrodi; Hans Rudolf (Sodertalje, SW), Ek; Lars (Onsala, SW), Ablad; Bengt Arne-Hjalmar (Goteborg, SW)
Assignee: Aktiebolaget Hassle (Goteborg, SW)
Filing Date:Jan 15, 1974
Application Number:05/433,450
Claims:1. A pharmaceutical preparation for treatment of cardiovascular diseases which comprises as an active ingredient a therapeutically effective dose of at least one para-substituted phenoxy-hydroxypropylamine compound selected from the group consisting of a compound having the formula ##SPC18##

and a pharmaceutically acceptable, non-toxic acid addition salt thereof, wherein R' is an isopropyl or tertiary-butyl radical; Z is NHCOOR", R" being a straight or branched alkyl radical having 1 to 3 carbon atoms and n is 1, 2 or 3, in association with a pharmaceutically acceptable carrier.

2. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound in racemic form.

3. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound as the optically active, dextrorotatary isomer.

4. A pharmaceutical preparation according to claim 1 wherein the active ingredient is a therapeutically effective dose of at least one said compound as the optically active, levorotatary isomer.

5. A pharmaceutical preparation according to claim 1 wherein the para-substituted phenoxy-hydroxypropylamine compound comprises 0.1 to 95% by weight of the preparation.

6. A pharmaceutical preparation according to claim 1 in a form suitable for administration by injection wherein the para-substituted phenoxy-hydroxypropylamine compound comprises about 0.5% to about 20% by weight of the preparation.

7. A pharmaceutical preparation according to claim 6 for parenteral application which comprises an aqueous solution of a water soluble salt of said para-substituted phenoxy-hydroxy-propylamine compound in an amount of about 0.5 - 10% by weight of the preparation.

8. A pharmaceutical preparation according to claim 1 in a form suitable for oral administration wherein the para-substituted phenoxy-hydroxypropylamine compound comprises about 0.2% to about 50% by weight of the preparation.

9. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein R' is isopropyl in association with a pharmaceutically acceptable carrier.

10. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 wherein R' is tertiarybutyl in association with a pharmaceutically acceptable carrier.

11. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 (.+-.) -1-isopropylamino -3-[p-(.beta.-methoxycarbinylamidoethyl)-phenoxy]-propanol-2 and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.

12. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 (-)-1-isopropylamino -3-[p-(.beta.-methoxycarbinylamidoethyl)-phenoxy]-propanol-2 and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.

13. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 (+)-1-isopropylamino-3-[p-(.beta.-methoxycarbinamidoethyl)-phenoxy]-propan ol-2 and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.

14. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 1-isopropylamino-3-[p-(.gamma.-methoxycarbonylamidopropyl)-phenoxy]-propan ol-2 and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.

15. A pharmaceutical preparation wherein the active ingredient is the compound of claim 1 1-tertiarybutylamino-3-[p-(.beta.-methoxycarbinylamidoethyl)-phenoxy]-prop anol-2 and a pharmaceutically acceptable, non-toxic acid addition salt thereof in association with a pharmaceutically acceptable carrier.

16. A method for treating cardiovascular diseases in animals including humans which comprises administering a therapeutically effective dose of a para-substituted phenoxyhydroxypropylamine compound selected from the group consisting essentially of a compound having the formula ##SPC19##

and a pharmaceutically acceptable, non-toxic acid addition salt thereof, wherein R' is an isopropyl or tertiary-butyl radical; Z is --NHCOOR", R" being a straight or branched alkyl radical having 1 to 3 carbon atoms: and n is 1, 2 or 3, in association with a pharmaceutically acceptable carrier.

17. A method for treating cardiovascular diseases in animals including humans, which comprises administering a therapeutically effective dose of a parasubstituted phenoxyhydroxypropylamine compound according to claim 16 wherein R' is isopropyl.

18. A method for treating cardiovascular diseases in animals including humans, which comprises administering a therapeutically effective dose of a parasubstituted phenoxyhydroxypropylamine compound according to claim 16 wherein R' is tertiarybutyl.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc